SCHEMBL1157558

SCHEMBL1157558

COc1ccc(/C=N/NC(=N)NO)cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
KDM4E B2RXH2 5/20 0.54
ALDH1A1 P00352 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
GAA P10253 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
GFER P55789 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.49
USP2 O75604 1/20 0.49
POLB P06746 1/20 0.49
LMNA P02545 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HPGD P15428 2/20 0.45
MMP9 P14780 1/20 0.45
TLR9 Q9NR96 1/20 0.45
TUBB1 Q9H4B7 2/20 0.44
RECQL P46063 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157559 1.00 MAPT (0.56) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL13673570 0.86 SMN1; SMN2 (0.60) MAPTALDH1A1SMN1; SMN2GAAMEN1
SCHEMBL7747517 0.86 MAPT (0.56) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL13673573 0.86 SMN1; SMN2 (0.60) MAPTALDH1A1SMN1; SMN2GAAMEN1
SCHEMBL7747519 0.86 MAPT (0.56) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL915517 0.86 ALDH1A1 (0.52) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL915515 0.86 ALDH1A1 (0.52) MAPTKDM4EALDH1A1SMN1; SMN2GAA
Hydrochloric Acid SCHEMBL915893 0.85 MAPT (0.55) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL13673609 0.85 MAPT (0.47) MAPTKDM4EALDH1A1SMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL915892 0.85 MAPT (0.55) MAPTKDM4EALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410174-B2 Method for treating arthritis ANAMAR AB (SE) 2013-04-02 US disclosed
US-8309609-B2 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands ANAMAR AB (SE) 2012-11-13 US disclosed
US-20120190751-A1 COMPOUNDS FOR TREATMENTS OF INFLAMMATION ANA-MAR AB (SE) 2012-07-26 US disclosed
EP-2470270-A1 COMPOUNDS FOR TREATMENT OF INFLAMMATION AnaMar AB (SE) 2012-07-04 EP disclosed
WO-2011012868-A1 COMPOUNDS FOR TREATMENT OF INFLAMMATION ANAMAR AB (SE) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190751-A1 COMPOUNDS FOR TREATMENTS OF INFLAMMATION IL6, IL1B, TNF MAPT 3564/4885KDM4E 597/4885ALDH1A1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.